Marcus Sandling
Infectious Disease · Brooklyn, NYNPI 1396001418
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,815 of the $156,792 with a category attached, or 66.2%. Viiv Healthcare Company accounts for 71.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $81,917, more than ten times the $453 reported in 2019. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $725.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$112K
- Gilead$43K
- Bavarian Nordic A/s$750
- Johnson & Johnson$171
- Janssen Products, LP$121
- Merck$73
What the payments were for
- Consulting fees$26,22017%
- Speaking & faculty fees$103,81566%
- Travel & lodging$20,15313%
- Food & beverage$6,6044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 134 | $112,427 |
| Gilead | 65 | $43,249 |
| Bavarian Nordic A/s | 1 | $750 |
| Johnson & Johnson | 10 | $171 |
| Janssen Products, LP | 1 | $121 |
| Merck | 5 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$156,792 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 50 | $222,158 |
| DovatoDolutegravir Sodium/Lamivudine | 25 | $74,044 |
| CreonLipase/Protease/Amylase | 16 | $60,476 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $37,303 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $447 |
| Atorvastatin Calcium | 23 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $43,249 | $222,15850 claims |
| Viiv Healthcare CompanyDovato | $112,427 | $74,04425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 799 infectious disease providers in New York.
Other infectious disease in Brooklyn
- Andre BrutusBrooklyn$303K
- Joseph PaulBrooklyn$186K
- Alan SteinBrooklyn$90K
- Jessica YagerBrooklyn$70K
- Yusuf AfacanBrooklyn$19K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.